NNC 26-0161
Evidence Grade C — Moderate human evidence. 44 published studies, 19 human. 2 registered clinical trials.
Ipamorelin is a research peptide that stimulates your body's natural growth hormone production. Originally developed by Novo Nordisk, it showed a more selective profile than older compounds in the same class — stimulating growth hormone without significantly affecting cortisol or prolactin. Despite this advantage, its only clinical trial (for post-operative bowel recovery) failed, and it was never brought to market.
44 published studies: 19 human, 20 animal, 10 in-vitro, 3 reviews
Ipamorelin has no marketing authorisation. A Phase II trial in post-operative ileus (approximately 114 patients) did not demonstrate significant acceleration of bowel function recovery. Phase I data confirmed dose-dependent growth hormone elevation without cortisol or prolactin changes.
The compound's clinical development was not advanced beyond Phase II. It is widely available through unregulated channels, often combined with CJC-1295. These combinations have no clinical trial support. Products from unregulated sources lack pharmaceutical quality assurance.
Research suggests ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells. Early-phase studies indicated it may stimulate growth hormone release with less effect on cortisol and prolactin compared to earlier compounds in this class. These observations are from Phase I pharmacokinetic data and have not been confirmed in efficacy-focused clinical trials.
Research suggests ipamorelin's Phase I data confirmed dose-dependent growth hormone elevation without the cortisol or prolactin spikes seen with GHRP-2 and GHRP-6 — a selectivity advantage that made it the most popular growth hormone secretagogue in unregulated channels. A Phase II trial for post-operative ileus (approximately 114 patients) did not demonstrate significant efficacy. No long-term safety data, no efficacy data for any clinical outcome, and no established dosing exist. The widely used combination with CJC-1295 has no clinical trial support whatsoever. Products from unregulated sources lack pharmaceutical quality assurance.
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Somatropin has been available since the mid-1980s and is one of the most established peptide therapies. It is sold under numerous brand names including Genotropin, Humatrope, Norditropin, and Omnitrope (the first biosimilar approved in the US, 2006). Approved indications include childhood and adult growth hormone deficiency, Turner syndrome, children born small for gestational age, Prader-Willi syndrome, idiopathic short stature, and short stature from chronic kidney disease. Daily injection has been the main burden of somatropin therapy, particularly for paediatric patients who may require years of treatment. This has driven the development of once-weekly alternatives (somatrogon and somapacitan), which are gradually changing the treatment landscape. Annual treatment costs remain substantial, and concerns about misuse in anti-ageing and performance enhancement contexts are ongoing.
Tesamorelin is marketed as Egrifta SV (approved November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In clinical trials, it reduced visceral fat by approximately 15% compared to a 5% increase with placebo, and this reduction was sustained with continued treatment. Tesamorelin occupies a unique niche — it is the only approved GHRH analogue and the only medication specifically approved for HIV-associated lipodystrophy. Beyond its approved indication, it has attracted research interest for potential effects on liver fat, cognitive function, and peripheral neuropathy. Fat reduction reverses when treatment stops, and it is not approved for general weight loss or body composition purposes.
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
